Abstract
Zerumbone found in subtropical ginger Zingiber zerumbet Smith exhibits antiproliferative and antiinflammatory activities but underlying molecular mechanisms are poorly understood. As several genes that regulate proliferation and apoptosis are regulated by nuclear factor (NF)-κB, we hypothesized that zerumbone mediates its activity through the modulation of NF-κB activation. We found that zerumbone suppressed NF-κB activation induced by tumor necrosis factor (TNF), okadaic acid, cigarette smoke condensate, phorbol myristate acetate, and H2O2 and that the suppression was not cell type specific. Interestingly, α-humulene, a structural analogue of zerumbone lacking the carbonyl group, was completely inactive. Besides being inducible, constitutively active NF-κB was also inhibited. NF-κB inhibition by zerumbone correlated with sequential suppression of the IκBα kinase activity, IκBα phosphorylation, IκBα degradation, p65 phosphorylation, p65 nuclear translocation, and p65 acylation. Zerumbone also inhibited the NF-κB-dependent reporter gene expression activated by TNF, TNFR1, TRADD, TRAF2, NIK, and IKK but not that activated by the p65 subunit of NF-κB. NF-κB-regulated gene products, such as cyclin D1, COX-2, MMP-9, ICAM-1, c-Myc, survivin, IAP1, IAP2, XIAP, Bcl-2, Bcl-xL, Bfl-1/A1, TRAF1 and FLIP, were all downregulated by zerumbone. This downregulation led to the potentiation of apoptosis induced by cytokines and chemotherapeutic agents. Zerumbone's inhibition of expression of these NF-κB-regulated genes also correlated with the suppression of TNF-induced invasion activity. Overall, our results indicated that zerumbone inhibits the activation of NF-κB and NF-κB-regulated gene expression induced by carcinogens and that this inhibition may provide a molecular basis for the prevention and treatment of cancer by zerumbone.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- NF-κB:
-
nuclear factor-κB
- IκB:
-
inhibitory subunit of NF-κB
- IKK:
-
IκBα kinase
- NIK:
-
NF-κB-inducing kinase
- TNF:
-
tumor necrosis factor
- SEAP:
-
secretory alkaline phosphatase
- PMA:
-
phorbol myristate acetate
- TUNEL:
-
terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end-labeling
- IL:
-
interleukin
- FADD:
-
Fas-associated death domain protein
- FLICE:
-
FADD-like interleukin-1β-converting enzyme
- FLIP:
-
FLICE-inhibitory protein
- COX:
-
cyclooxygenase
- MMP:
-
matrix metalloproteinase
- TRAF:
-
TNF receptor-associated factor
- PBS:
-
phosphate-buffered saline
References
Anto RJ, Mukhopadhyay A, Shishodia S, Gairola CG and Aggarwal BB . (2002). Carcinogenesis, 23, 1511–1518.
Bonizzi G, Piette J, Merville MP and Bours V . (1997). J. Immunol., 159, 5264–5272.
Catz SD and Johnson JL . (2001). Oncogene., 20, 7342–7351.
Chaturvedi MM, LaPushin R and Aggarwal BB . (1994). J. Biol. Chem., 269, 14575–14583.
Chu ZL, McKinsey TA, Liu L, Gentry JJ, Malim MH and Ballard DW . (1997). Proc. Natl. Acad. Sci. USA, 94, 10057–10062.
Dev S . (1956). Chem. Ind., 1051.
Duyao MP, Kessler DJ, Spicer DB, Bartholomew C, Cleveland JL, Siekevitz M and Sonenshein GE . (1992). J. Biol. Chem., 267, 16288–16291.
Esteve PO, Chicoine E, Robledo O, Aoudjit F, Descoteaux A, Potworowski EF and St-Pierre Y . (2002). J. Biol. Chem., 277, 35150–35155.
Garg A and Aggarwal BB . (2002). Leukemia, 16, 1053–1068.
Ghosh S and Karin M . (2002). Cell, 109 (Suppl), S81–S96.
Ghosh S, May MJ and Kopp EB . (1998). Annu. Rev. Immunol., 16, 225–260.
Giri DK and Aggarwal BB . (1998). J. Biol. Chem., 273, 14008–14014.
Grumont RJ, Rourke IJ and Gerondakis S . (1999). Genes Dev., 13, 400–411.
Guttridge DC, Albanese C, Reuther JY, Pestell RG and Baldwin Jr AS . (1999). Mol. Cell. Biol., 19, 5785–5799.
Higuchi M, Singh S, Chan H and Aggarwal BB . (1995). Blood, 86, 2248–2256.
Hirschowitz E, Hidalgo G and Doherty D . (2002). Gene. Ther., 9, 81–84.
Hiscott J, Marois J, Garoufalis J, D'Addario M, Roulston A, Kwan I, Pepin N, Lacoste J, Nguyen H, Bensi G and Fenton M . (1993). Mol. Cell. Biol., 13, 6231–6240.
Hsu H, Shu HB, Pan MG and Goeddel DV . (1996). Cell, 84, 299–308.
Kirana C, McIntosh GH, Record IR and Jones GP . (2003). Nutr. Cancer, 45, 218–225.
Kitayama T, Okamoto T, Hill RK, Kawai Y, Takahashi S, Yonemori S, Yamamoto Y, Ohe K, Uemura S and Sawada S . (1999). J. Org. Chem., 64, 2667–2672.
Kreuz S, Siegmund D, Scheurich P and Wajant H . (2001). Mol. Cell. Biol., 21, 3964–3973.
Liotta LA, Thorgeirsson UP and Garbisa S . (1982). Cancer Metastasis Rev., 1, 277–288.
Mahon TM and O'Neill LA . (1995). J. Biol. Chem., 270, 28557–28564.
Mayo MW, Wang CY, Cogswell PC, Rogers-Graham KS, Lowe SW, Der CJ and Baldwin Jr AS . (1997). Science, 278, 1812–1815.
Morris KR, Lutz RD, Choi HS, Kamitani T, Chmura K and Chan ED . (2003). Infect. Immun., 71, 1442–1452.
Mukhopadhyay A, Banerjee S, Stafford LJ, Xia C, Liu M and Aggarwal BB . (2002). Oncogene, 21, 8852–8861.
Murakami A, Hayashi R, Tanaka T, Kwon KH, Ohigashi H and Safitri R . (2003a). Biochem. Pharmacol., 66, 1253–1261.
Murakami A, Matsumoto K, Koshimizu K and Ohigashi H . (2003b). Cancer Lett., 195, 17–25.
Murakami A, Takahashi D, Kinoshita T, Koshimizu K, Kim HW, Yoshihiro A, Nakamura Y, Jiwajinda S, Terao J and Ohigashi H . (2002). Carcinogenesis, 23, 795–802.
Murakami A, Takahashi D, Koshimizu K and Ohigashi H . (2003c). Mutat. Res., 523–524, 151–161.
Murakami A, Takahashi M, Jiwajinda S, Koshimizu K and Ohigashi H . (1999). Biosci. Biotechnol. Biochem., 63, 1811–1812.
Murakami A, Tanaka T, Lee JY, Surh YJ, Kim HW, Kawabata K, Nakamura Y, Jiwajinda S and Ohigashi H . (2004). Int. J. Cancer, 110, 481–490.
Nasuhara Y, Adcock IM, Catley M, Barnes PJ and Newton R . (1999). J. Biol. Chem., 274, 19965–19972.
Natarajan K, Singh S, Burke Jr TR, Grunberger D and Aggarwal BB . (1996). Proc. Natl. Acad. Sci. USA, 93, 9090–9095.
Newman DJ, Cragg GM and Snader KM . (2003). J. Nat. Prod., 66, 1022–1037.
Ozaki Y, Kawahara N and Harada M . (1991). Chem. Pharm. Bull. (Tokyo), 39, 2353–2356.
Pahl HL . (1999). Oncogene, 18, 6853–6866.
Pomerantz JL and Baltimore D . (2000). Nature, 406, 26–27 29.
Schwenzer R, Siemienski K, Liptay S, Schubert G, Peters N, Scheurich P, Schmid RM and Wajant H . (1999). J. Biol. Chem., 274, 19368–19374.
Shakhov AN, Collart MA, Vassalli P, Nedospasov SA and Jongeneel CV . (1990). J. Exp. Med., 171, 35–47.
Shiraga M, Yano S, Yamamoto A, Ogawa H, Goto H, Miki T, Miki K, Zhang H and Sone S . (2002). Cancer Res., 62, 5967–5973.
Shishodia S, Majumdar S, Banerjee S and Aggarwal BB . (2003). Cancer Res., 63, 4375–4383.
Simeonidis S, Stauber D, Chen G, Hendrickson WA and Thanos D . (1999). Proc. Natl. Acad. Sci. USA, 96, 49–54.
Stancovski I and Baltimore D . (1997). Cell, 91, 299–302.
Stehlik C, de Martin R, Kumabashiri I, Schmid JA, Binder BR and Lipp J . (1998). J. Exp. Med., 188, 211–216.
Takada Y and Aggarwal BB . (2003). J. Immunol., 171, 3278–3286.
Takada Y and Aggarwal BB . (2004). J. Biol. Chem., 279, 4750–4759.
Takada Y, Khuri FR and Aggarwal BB . (2004). J. Biol. Chem., 279, 26287–26299.
Takada Y, Mukhopadhyay A, Kundu GC, Mahabeleshwar GH, Singh S and Aggarwal BB . (2003). J. Biol. Chem., 278, 24233–24241.
Tamatani M, Che YH, Matsuzaki H, Ogawa S, Okado H, Miyake S, Mizuno T and Tohyama M . (1999). J. Biol. Chem., 274, 8531–8538.
Tanaka T, Shimizu M, Kohno H, Yoshitani S, Tsukio Y, Murakami A, Safitri R, Takahashi D, Yamamoto K, Koshimizu K, Ohigashi H and Mori H . (2001). Life Sci., 69, 1935–1945.
van de Stolpe A, Caldenhoven E, Stade BG, Koenderman L, Raaijmakers JA, Johnson JP and van der Saag PT . (1994). J. Biol. Chem., 269, 6185–6192.
Verma IM and Stevenson J . (1997). Proc. Natl. Acad. Sci. USA, 94, 11758–11760.
Vinitsky A, Michaud C, Powers JC and Orlowski M . (1992). Biochemistry, 31, 9421–9428.
Wang CY, Mayo MW, Korneluk RG, Goeddel DV and Baldwin Jr AS . (1998). Science, 281, 1680–1683.
Weinstein IB . (2000). Carcinogenesis, 21, 857–864.
Xu P, Huecksteadt TP and Hoidal JR . (1996). Genomics, 34, 173–180.
Yamamoto K, Arakawa T, Ueda N and Yamamoto S . (1995). J. Biol. Chem., 270, 31315–31320.
You M, Ku PT, Hrdlickova R and Bose Jr HR . (1997). Mol. Cell. Biol., 17, 7328–7341.
Zhu L, Fukuda S, Cordis G, Das DK and Maulik N . (2001). FEBS Lett., 508, 369–374.
Zong WX, Edelstein LC, Chen C, Bash J and Gelinas C . (1999). Genes Dev., 13, 382–387.
Acknowledgements
We would like to thank Gayle Nesom for carefully editing this manuscript. Dr Takada is an Odyssey Program Special Fellow. Dr Aggarwal is a Ransom Horne, Jr Professor of Cancer Research. This work was supported by the Theodore N Law Award Scientific Achievement Fund from The University of Texas MD Anderson Cancer Center (to YT), the Clayton Foundation for Research (to BBA), Department of Defense US Army Breast Cancer Research Program Grant (BC010610, to BBA), a PO1 Grant (CA91844) from the National Institutes of Health on lung chemoprevention (to BBA), and a P50 Head and Neck SPORE grant from the National Institutes of Health (p50CA97007, to BBA).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Takada, Y., Murakami, A. & Aggarwal, B. Zerumbone abolishes NF-κB and IκBα kinase activation leading to suppression of antiapoptotic and metastatic gene expression, upregulation of apoptosis, and downregulation of invasion. Oncogene 24, 6957–6969 (2005). https://doi.org/10.1038/sj.onc.1208845
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1208845
Keywords
This article is cited by
-
Cellular and molecular antiproliferative effects in 2D monolayer and 3D-cultivated HT-29 cells treated with zerumbone
Naunyn-Schmiedeberg's Archives of Pharmacology (2024)
-
Anti-cancer potential of zerumbone in cancer and glioma: current trends and future perspectives
Medical Oncology (2024)
-
Phytochemical mediated modulation of COX-3 and NFκB for the management and treatment of arthritis
Scientific Reports (2023)
-
Advances in glioma-associated oncogene (GLI) inhibitors for cancer therapy
Investigational New Drugs (2022)
-
Lactucin induces apoptosis through reactive oxygen species-mediated BCL-2 and CFLARL downregulation in Caki-1 cells
Genes & Genomics (2021)